Browse All

Current Filters

CLEAR FILTER x

TITLE

Time to Progression to Wheelchair Comparing Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia (SCA)

Author:Kuo, Sheng-Han   Rosenthal, Liana   L'Italien, Gilbert   Potashman, Michele   Beiner, Melissa   Wirtz, Victoria   Qureshi, Irfan   Perlman, Susan   Coric, Vladimir   Schmahmann, Jeremy   

Session Name:S26: Movement Disorders: Clinical Trials and Therapeutics  

Topic:Movement Disorders  

Program Number:S26.009  

Author Institution:Columbia University, New York, NY  Johns Hopkins School of Medicine, Lutherville, MD  Biohaven Pharmaceuticals, CT  Biohaven Pharmaceuticals, New Haven, CT  UCLA, Los Angeles, CA  Massachusettes General Hospital, Boston, MA  

Opakalim (BHV-7000) Potentiates the Activity of Kv7.2/7.3 Channels Containing a Single Copy of the Kv7.2 DEE-Causing Mutation, G281E

Author:Spitznagel, Brittany   Komarov, Alexander   DeMarco, Ulrike   Smith, Kelly   Wang, Ling-Xin   Resnick, Lynn   Picchione, Kelly   Lerner, Jason   Weaver, David   Dworetzky, Steven   Bozik, Michael   

Session Name:P3: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Mechanisms and Pharmacology  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P3.009  

Author Institution:Biohaven Pharmaceuticals, CT  Biohaven Pharmaceuticals, Pittsburgh, PA  Biohaven Pharmaceuticals, New Haven, CT  

A Novel Mechanism for the Treatment of Autoimmune Neurologic Diseases: Robust, Rapid, and Tunable Removal of IgG with the MoDE™ Degrader BHV-1300

Author:Awsare, Bharat   Granit, Volkan   Ashbrenner, Eric   Killingsworth, Randall   Bertz, Richard   Car, Bruce   Spiegel, David   Gardin, Tova   Coric, Vladimir   

Session Name:P5: Autoimmune Neurology: Rheumatology 1  

Topic:Autoimmune Neurology  

Program Number:P5.004  

Author Institution:Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Hollywood, FL  Biohaven Pharmaceuticals, Kaukauna, WI  Biohaven Pharmaceuticals, Cambridge, MA  Yale University, New Haven, CT  Biohaven Pharmaceuticals, CT  

Compassionate Use of Kv7.2/7.3 Potassium Channel Activator Opakalim (BHV-7000) in a Child with KCNQ2 Developmental and Epileptic Encephalopathy

Author:Olson, Heather   Maguire-Lobos, Eorna   Mansour, Kathryn   Correa, Grace   Lerner, Jason   Bozik, Michael   Dworetzky, Steven   Sevinsky, Heather   Sweeney, Kelly   Potashman, Michele   Paul, Prokash   Kendrick, Racheal   Donatelli, Stephanie   Patel, Archana   Wiltrout, Kimberly   Achkar, Christelle   Poduri, Annapurna   

Session Name:P10: Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy Reports and Studies  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P10.002  

Author Institution:Boston Children's Hospital, Peabody, MA  Boston Children's Hospital, MA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Pittsburgh, PA  Biohaven Pharmaceuticals, CT  Certara, PA  Certara, Princeton, NJ  Boston Children's Hospital, Boston, MA